Drugs / NO-13065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04838639 | Jun 2021 → Mar 2022 | obesity disorder | Otsuka Pharmaceutical Factory, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NO-13065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04838639 ↗ |
| Route | Oral | “When Administered Orally” NCT04838639 ↗ |